12/5
08:37 am
alpmy
Astellas To Present New Data on XOSPATA™ (gilteritinib) Across the FLT3m+ AML Disease Continuum at ASH 2025 Annual Meeting [Yahoo! Finance]
Low
Report
Astellas To Present New Data on XOSPATA™ (gilteritinib) Across the FLT3m+ AML Disease Continuum at ASH 2025 Annual Meeting [Yahoo! Finance]
12/5
08:00 am
alpmy
Astellas To Present New Data on XOSPATA™ (gilteritinib) Across the FLT3m+ AML Disease Continuum at ASH 2025 Annual Meeting
Low
Report
Astellas To Present New Data on XOSPATA™ (gilteritinib) Across the FLT3m+ AML Disease Continuum at ASH 2025 Annual Meeting
11/22
07:17 am
alpmy
Astellas Pharma (TSE:4503): Exploring Valuation After Strong 21% Monthly Share Price Rally [Yahoo! Finance]
Low
Report
Astellas Pharma (TSE:4503): Exploring Valuation After Strong 21% Monthly Share Price Rally [Yahoo! Finance]
11/19
09:52 am
alpmy
Lung Transplant Rejection Research Report 2025-2035: TFF Pharmaceuticals and Astellas Lead by Investing Heavily in R&D to Improve Existing Immunosuppressive Therapies, and Develop New Biologics [Yahoo! Finance]
Low
Report
Lung Transplant Rejection Research Report 2025-2035: TFF Pharmaceuticals and Astellas Lead by Investing Heavily in R&D to Improve Existing Immunosuppressive Therapies, and Develop New Biologics [Yahoo! Finance]
10/24
05:32 am
alpmy
Astellas Pharma (OTCMKTS:ALPMY) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Low
Report
Astellas Pharma (OTCMKTS:ALPMY) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
10/23
08:00 am
alpmy
Astellas and the Internet's Favorite Grandma, Barbara 'Babs' Costello, Partner to Encourage Others to Get Ahead of Geographic Atrophy (GA)
Low
Report
Astellas and the Internet's Favorite Grandma, Barbara 'Babs' Costello, Partner to Encourage Others to Get Ahead of Geographic Atrophy (GA)
10/22
08:00 am
alpmy
Astellas Presents Preliminary Real-World VEOZAH™ (fezolinetant) Data From OPTION-VMS Phase IV Observational Study
Low
Report
Astellas Presents Preliminary Real-World VEOZAH™ (fezolinetant) Data From OPTION-VMS Phase IV Observational Study
10/21
07:30 pm
alpmy
PADCEV™ (enfortumab vedotin-ejfv) Plus KEYTRUDA® (pembrolizumab) sBLA Granted FDA Priority Review for Treatment of Certain Patients with Muscle-Invasive Bladder Cancer
Low
Report
PADCEV™ (enfortumab vedotin-ejfv) Plus KEYTRUDA® (pembrolizumab) sBLA Granted FDA Priority Review for Treatment of Certain Patients with Muscle-Invasive Bladder Cancer
10/19
07:53 pm
alpmy
IZERVAY™ (avacincaptad pegol intravitreal solution) Showed Increased Benefit in Reducing Geographic Atrophy Progression Over Time and Consistent Long-Term Safety [Yahoo! Finance]
Low
Report
IZERVAY™ (avacincaptad pegol intravitreal solution) Showed Increased Benefit in Reducing Geographic Atrophy Progression Over Time and Consistent Long-Term Safety [Yahoo! Finance]
10/19
07:30 pm
alpmy
IZERVAY™ (avacincaptad pegol intravitreal solution) Showed Increased Benefit in Reducing Geographic Atrophy Progression Over Time and Consistent Long-Term Safety
Low
Report
IZERVAY™ (avacincaptad pegol intravitreal solution) Showed Increased Benefit in Reducing Geographic Atrophy Progression Over Time and Consistent Long-Term Safety
10/18
10:34 am
alpmy
PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer [Yahoo! Finance]
Low
Report
PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer [Yahoo! Finance]
10/14
08:00 pm
alpmy
Astellas to Present First Real-World VEOZAH™ (fezolinetant) Data at 2025 Annual Meeting of The Menopause Society
Low
Report
Astellas to Present First Real-World VEOZAH™ (fezolinetant) Data at 2025 Annual Meeting of The Menopause Society
10/8
08:02 pm
alpmy
Astellas to Present New Data on IZERVAY™ (avacincaptad pegol intravitreal solution) in Geographic Atrophy at AAO 2025 Annual Meeting [Yahoo! Finance]
Low
Report
Astellas to Present New Data on IZERVAY™ (avacincaptad pegol intravitreal solution) in Geographic Atrophy at AAO 2025 Annual Meeting [Yahoo! Finance]
10/8
07:30 pm
alpmy
Astellas to Present New Data on IZERVAY™ (avacincaptad pegol intravitreal solution) in Geographic Atrophy at AAO 2025 Annual Meeting
Low
Report
Astellas to Present New Data on IZERVAY™ (avacincaptad pegol intravitreal solution) in Geographic Atrophy at AAO 2025 Annual Meeting
10/7
10:38 am
alpmy
Astellas Pharma (TSE:4503): Evaluating Valuation Potential with Shares in a Stable Trading Range [Yahoo! Finance]
Low
Report
Astellas Pharma (TSE:4503): Evaluating Valuation Potential with Shares in a Stable Trading Range [Yahoo! Finance]
10/1
08:06 pm
alpmy
VYLOY® (zolbetuximab) in Combination with Chemotherapy for Advanced Gastric or Gastroesophageal Junction Cancer is now funded in both Ontario and Quebec [Yahoo! Finance]
Low
Report
VYLOY® (zolbetuximab) in Combination with Chemotherapy for Advanced Gastric or Gastroesophageal Junction Cancer is now funded in both Ontario and Quebec [Yahoo! Finance]
10/1
02:14 am
alpmy
Astellas To Present Pioneering Advances Across Its Portfolio and Pipeline at ESMO 2025 [Yahoo! Finance]
Low
Report
Astellas To Present Pioneering Advances Across Its Portfolio and Pipeline at ESMO 2025 [Yahoo! Finance]
10/1
02:00 am
alpmy
Astellas To Present Pioneering Advances Across Its Portfolio and Pipeline at ESMO 2025
Low
Report
Astellas To Present Pioneering Advances Across Its Portfolio and Pipeline at ESMO 2025
9/29
02:00 am
alpmy
Astellas Announces Top Management Personnel Change
Low
Report
Astellas Announces Top Management Personnel Change
9/11
07:13 am
alpmy
Astellas Pharma (OTCMKTS:ALPMY) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Low
Report
Astellas Pharma (OTCMKTS:ALPMY) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.